secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001493152-24-046001
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharma Q2 FY2025 revenue $18.9M (+33% YoY); operating profit $3.5M (+84%)
-------------------------------------------------------------------------------

- Consolidated revenue $18.9M for Q2 ended Sep 30, 2024, up $4.7M or 33% vs prior year.
- Operating profit $3.5M, up $1.6M or 84% YoY, driven by higher Elite label product sales.
- Conference call scheduled for Nov 15, 2024 at 11:30 AM EST to discuss results and business update.
- Stockholders can submit financial questions by 7 PM EST on Nov 14 via dianne@elitepharma.com.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224046001/0001493152-24-046001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224046001/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-046001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer